The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Acute Ischemic Stroke Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.
The global Acute Ischemic Stroke Therapeutics market size is expected to reach US$ 8110.8 million by 2029, growing at a CAGR of 4.4% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Ischemic Stroke Therapeutics in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Center and Diagnostic Centers,, are propelling Acute Ischemic Stroke Therapeutics market. Thrombolytic Therapeutics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antihypertensive Therapeutics segment is estimated at % CAGR for the next seven-year period.
Technavio's analysts forecast the global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2025.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Ischemic Stroke Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Ischemic Stroke Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Ischemic Stroke Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Ischemic Stroke Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Ischemic Stroke Therapeutics covered in this report include Bayer, Boehringer Ingelheim, Roche, Sanofi, Biogen, Daiichi Sankyo and Pfizer, etc.
The global Acute Ischemic Stroke Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Boehringer Ingelheim
Roche
Sanofi
Biogen
Daiichi Sankyo
Pfizer
Global Acute Ischemic Stroke Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Ischemic Stroke Therapeutics market, Segment by Type:
Thrombolytic Therapeutics
Antihypertensive Therapeutics
Antiplatelet Therapeutics
Anticoagulants
Global Acute Ischemic Stroke Therapeutics market, by Application
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acute Ischemic Stroke Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.
The global Acute Ischemic Stroke Therapeutics market size is expected to reach US$ 8110.8 million by 2029, growing at a CAGR of 4.4% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Ischemic Stroke Therapeutics in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Center and Diagnostic Centers,, are propelling Acute Ischemic Stroke Therapeutics market. Thrombolytic Therapeutics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antihypertensive Therapeutics segment is estimated at % CAGR for the next seven-year period.
Technavio's analysts forecast the global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2025.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Ischemic Stroke Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Ischemic Stroke Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Ischemic Stroke Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Ischemic Stroke Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Ischemic Stroke Therapeutics covered in this report include Bayer, Boehringer Ingelheim, Roche, Sanofi, Biogen, Daiichi Sankyo and Pfizer, etc.
The global Acute Ischemic Stroke Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Boehringer Ingelheim
Roche
Sanofi
Biogen
Daiichi Sankyo
Pfizer
Global Acute Ischemic Stroke Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Ischemic Stroke Therapeutics market, Segment by Type:
Thrombolytic Therapeutics
Antihypertensive Therapeutics
Antiplatelet Therapeutics
Anticoagulants
Global Acute Ischemic Stroke Therapeutics market, by Application
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acute Ischemic Stroke Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Acute Ischemic Stroke Therapeutics
1.1 Acute Ischemic Stroke Therapeutics Market Overview
1.1.1 Acute Ischemic Stroke Therapeutics Product Scope
1.1.2 Acute Ischemic Stroke Therapeutics Market Status and Outlook
1.2 Global Acute Ischemic Stroke Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Acute Ischemic Stroke Therapeutics Market Size by Region (2018-2029)
1.4 Global Acute Ischemic Stroke Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Acute Ischemic Stroke Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Acute Ischemic Stroke Therapeutics Market Size (2018-2029)
1.6.1 North America Acute Ischemic Stroke Therapeutics Market Size (2018-2029)
1.6.2 Europe Acute Ischemic Stroke Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Acute Ischemic Stroke Therapeutics Market Size (2018-2029)
1.6.4 Latin America Acute Ischemic Stroke Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Acute Ischemic Stroke Therapeutics Market Size (2018-2029)
2 Acute Ischemic Stroke Therapeutics Market by Type
2.1 Introduction
2.1.1 Thrombolytic Therapeutics
2.1.2 Antihypertensive Therapeutics
2.1.3 Antiplatelet Therapeutics
2.1.4 Anticoagulants
2.2 Global Acute Ischemic Stroke Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Acute Ischemic Stroke Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Acute Ischemic Stroke Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Acute Ischemic Stroke Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Acute Ischemic Stroke Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Acute Ischemic Stroke Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Acute Ischemic Stroke Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Acute Ischemic Stroke Therapeutics Revenue Breakdown by Type (2018-2029)
3 Acute Ischemic Stroke Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Center
3.1.3 Diagnostic Centers
3.2 Global Acute Ischemic Stroke Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Acute Ischemic Stroke Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Acute Ischemic Stroke Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Acute Ischemic Stroke Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Acute Ischemic Stroke Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Acute Ischemic Stroke Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Acute Ischemic Stroke Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Acute Ischemic Stroke Therapeutics Revenue Breakdown by Application (2018-2029)
4 Acute Ischemic Stroke Therapeutics Competition Analysis by Players
4.1 Global Acute Ischemic Stroke Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acute Ischemic Stroke Therapeutics as of 2022)
4.3 Date of Key Players Enter into Acute Ischemic Stroke Therapeutics Market
4.4 Global Top Players Acute Ischemic Stroke Therapeutics Headquarters and Area Served
4.5 Key Players Acute Ischemic Stroke Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Acute Ischemic Stroke Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bayer
5.1.1 Bayer Profile
5.1.2 Bayer Main Business
5.1.3 Bayer Acute Ischemic Stroke Therapeutics Products, Services and Solutions
5.1.4 Bayer Acute Ischemic Stroke Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Bayer Recent Developments
5.2 Boehringer Ingelheim
5.2.1 Boehringer Ingelheim Profile
5.2.2 Boehringer Ingelheim Main Business
5.2.3 Boehringer Ingelheim Acute Ischemic Stroke Therapeutics Products, Services and Solutions
5.2.4 Boehringer Ingelheim Acute Ischemic Stroke Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Boehringer Ingelheim Recent Developments
5.3 Roche
5.3.1 Roche Profile
5.3.2 Roche Main Business
5.3.3 Roche Acute Ischemic Stroke Therapeutics Products, Services and Solutions
5.3.4 Roche Acute Ischemic Stroke Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Acute Ischemic Stroke Therapeutics Products, Services and Solutions
5.4.4 Sanofi Acute Ischemic Stroke Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 Biogen
5.5.1 Biogen Profile
5.5.2 Biogen Main Business
5.5.3 Biogen Acute Ischemic Stroke Therapeutics Products, Services and Solutions
5.5.4 Biogen Acute Ischemic Stroke Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Biogen Recent Developments
5.6 Daiichi Sankyo
5.6.1 Daiichi Sankyo Profile
5.6.2 Daiichi Sankyo Main Business
5.6.3 Daiichi Sankyo Acute Ischemic Stroke Therapeutics Products, Services and Solutions
5.6.4 Daiichi Sankyo Acute Ischemic Stroke Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Daiichi Sankyo Recent Developments
5.7 Pfizer
5.7.1 Pfizer Profile
5.7.2 Pfizer Main Business
5.7.3 Pfizer Acute Ischemic Stroke Therapeutics Products, Services and Solutions
5.7.4 Pfizer Acute Ischemic Stroke Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Pfizer Recent Developments
6 North America
6.1 North America Acute Ischemic Stroke Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Acute Ischemic Stroke Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Acute Ischemic Stroke Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Acute Ischemic Stroke Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Acute Ischemic Stroke Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Acute Ischemic Stroke Therapeutics Market Dynamics
11.1 Acute Ischemic Stroke Therapeutics Industry Trends
11.2 Acute Ischemic Stroke Therapeutics Market Drivers
11.3 Acute Ischemic Stroke Therapeutics Market Challenges
11.4 Acute Ischemic Stroke Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
